Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) insider Thomas Gad sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 240,032 shares of the […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) was up 7.5% during mid-day trading on Wednesday . The stock traded as high as $12.75 and last traded at $12.71. Approximately 31,560 shares were traded during trading, a decline of 92% from the average daily volume of 404,084 shares. The stock had previously closed at $11.82. […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $11.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 113.59% from the company’s current price. […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) Director Johan Wedell-Wedellsborg purchased 101,740 shares of the business’s stock in a transaction on Monday, May 15th. The stock was purchased at an average price of $9.65 per share, for a total transaction of $981,791.00. Following the acquisition, the director now owns 4,280,205 shares of the company’s stock, […]
Wedbush upgraded shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) from a neutral rating to an outperform rating in a report published on Wednesday morning, MarketBeat reports. They currently have $13.00 price objective on the stock, up from their prior price objective of $5.00. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q2 2023 earnings at […]